rawfin.tv
Guggenheim Initiates Solid Biosciences Coverage With Buy Rating, Citing FDA Potential
Top StoriesstocksAI Generated

Guggenheim Initiates Solid Biosciences Coverage With Buy Rating, Citing FDA Potential

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Guggenheim has begun coverage of Solid Biosciences (SLDB) with a Buy rating. The firm projects a potential FDA approval for the company's product, signaling a positive outlook for the biotechnology stock.

SLDBBiotechnologyAnalyst RatingsFDA Approval

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks